Back to Markets
Stocks● Neutral
Proscia Redesigns Concentriq Around AI for Faster Drug Development
Proscia’s Fifth Generation Concentriq uses domain-specific AI models to reduce manual workload in pathology, aiming to speed drug discovery and case review for 12 million annual cases.
Continue with
Proscia released the Fifth Generation of its Concentriq platform, a redesign that puts domain-specific AI models at the center of pathology workflows. The company said the new architecture lets pathologists focus on high-judgment decisions and helps scientists move from early signals to evidence-based program decisions.
The update arrives as pathology labs face a workload crunch. More than half of pathologists say they don't have enough time to get through their caseload, according to industry surveys cited by the company. Proscia's platform already handles 12 million patient cases a year and serves 16 of the top 20 pharmaceutical companies.
The Fifth Generation is the biggest change to Concentriq in five years, the company said. It required building a new technology stack from the ground up. The platform now integrates frontier vision, language, and multimodal models directly into the core infrastructure, with enterprise-grade security and governance. This lets it unify images, metadata, and case context – slide-level morphology, patient history, lab protocols, translational data – into a single picture that both experts and AI models see.